<DOC>
	<DOCNO>NCT02909452</DOCNO>
	<brief_summary>The objective study explore different dosing level schedule entinostat combination pembrolizumab patient advance solid tumor , term safety , tolerability , pharmacokinetics ( PK ) , impact immune correlative , efficacy</brief_summary>
	<brief_title>Continuation Study Entinostat Combination With Pembrolizumab Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase 1 , open-label , single center , randomize study ass safety tolerability 3 different dose regimen entinostat combination pembrolizumab patient advance solid tumor previously complete Study SNDX-275-0140 ( NCT02897778 ) . Up 30 patient randomize 1:1:1 fashion one three arm . In event great equal 2 first 6 patient randomized experience dose-limiting toxicity , next patient randomize Arm receive treatment reduce start dose outline protocol .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neoplasms Histologic Type</mesh_term>
	<mesh_term>Thoracic Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Respiratory Tract Neoplasms</mesh_term>
	<mesh_term>Bronchial Neoplasms</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Completed Study SNDX2750140 ( NCT02897778 ) 2 . Any AE toxicity experience Study SNDX2750140 ( NCT02897778 ) resolve less equal Grade 1 3 . Continues meet inclusion criterion Study SNDX2750140 ( NCT02897778 ) time entry study 1 . Completed Study SNDX2750140 ( NCT02897778 ) 30 day prior Cycle 1 Day 1 study 2 . Continues meet exclusion criterion Study SNDX2750140 ( NCT02897778 ) time entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>entinostat</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Histone Deacetylase Inhibitor</keyword>
</DOC>